AI generated
Sep 24, 2026, 14:33
Mohamed El Belghiti Alaoui: Thrombin as a Therapeutic Target in Coagulation
Mohamed El Belghiti Alaoui, Independent Researcher, shared a post on LinkedIn:
“Thrombin-catalyzed cleavage of fibrinogen into fibrin.
Consider how thrombin’s conversion of fibrinogen into fibrin safeguards you, guides tissue repair, and defines therapeutic targets.
This clotting cascade instantly forms a stable mesh that stops bleeding, supports platelet attachment for healing, and balances coagulation to prevent thrombosis or hemorrhage.
- Creates insoluble fibrin mesh, sealing vascular injury and preventing dangerous blood loss.
- Provides structural framework for platelet adhesion and wound healing, supporting tissue regeneration.
- Thrombin overactivity triggers pathological clotting, while deficiency causes hemorrhage-making it a key anticoagulant drug target.
How do you see modulating thrombin activity influencing patient outcomes?”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause